Assembly Biosciences (NASDAQ:ASMB) reported insider activity at the end of March that reflects routine tax-related selling connected to an equity award. According to a Form 4 filed with the Securities and Exchange Commission, Jeanette M. Bjorkquist - who holds the roles of Principal Financial Officer and Principal Accounting Officer - sold a total of 328 shares of the companys common stock on March 30, 2026.
The sales were executed in two separate transactions and produced proceeds of approximately $8,754. Transaction prices ranged from $26.65 to $27.49 per share. The filing specifies the purpose of the disposition as coverage of tax withholding obligations arising from the vesting and settlement of restricted stock units.
One day prior to those sales, on March 29, 2026, the filing shows that Bjorkquist was granted 6,500 shares of Assembly Biosciences common stock valued at $0 as part of a restricted stock unit award. The grant is scheduled to vest in installments through March 2030, according to the Form 4 disclosure.
Market context provided in the filing notes that Assembly Biosciences shares were trading at $27.75 at the time of reporting. That price point reflects a 179% gain over the trailing 12 months while marking a 22% decline so far year-to-date.
Separately, analysis available on InvestingPro is cited in the disclosure as indicating that ASMB remains on the platform's list of most undervalued stocks at current levels. The InvestingPro listing also highlights that the platform provides eight additional ProTips for investors following ASMB.
Summary of the filings and market snapshot
- Bjorkquist sold 328 shares across two transactions on March 30, 2026 for about $8,754.
- Transaction prices ranged from $26.65 to $27.49 per share.
- Sale proceeds were used to satisfy tax withholding tied to RSU vesting and settlement.
- On March 29, 2026, Bjorkquist received a 6,500-share RSU grant valued at $0 that vests through March 2030.
- ASMB traded at $27.75, up 179% over the past year and down 22% year-to-date.
- InvestingPro analysis lists ASMB as appearing undervalued and offers eight ProTips for investors.